Drug Patents owned by Mayne Pharma

1. List of Bijuva drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11529360 MAYNE PHARMA Natural combination hormone replacement formulations and therapies
Nov, 2032

(9 years from now)

Drugs and Companies using ESTRADIOL; PROGESTERONE ingredient

Market Authorisation Date: 28 October, 2018

Treatment: NA

Dosage: CAPSULE;ORAL

How can I launch a generic of BIJUVA before it's patent expiration?
More Information on Dosage

2. List of Doryx drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6958161 MAYNE PHARMA Modified release coated drug preparation
Dec, 2022

(a month ago)

US8715724 MAYNE PHARMA Tabletting process
Feb, 2028

(5 years from now)

US9295652 MAYNE PHARMA Controlled release doxycycline
Oct, 2034

(11 years from now)

US9511031 MAYNE PHARMA Controlled release doxycycline
Oct, 2034

(11 years from now)

US9446057 MAYNE PHARMA Controlled release doxycycline
Dec, 2034

(11 years from now)

Drugs and Companies using DOXYCYCLINE HYCLATE ingredient

Market Authorisation Date: 06 May, 2005

Treatment: To treat or prevent infections caused by susceptible bacteria using delayed-release tablets consisting of doxycycline hyclate coated pellets in a tablet

Dosage: TABLET, DELAYED RELEASE;ORAL

How can I launch a generic of DORYX before it's patent expiration?
More Information on Dosage

3. List of Fabior drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10568859 MAYNE PHARMA Topical foam composition
Feb, 2030

(7 years from now)

US10688071 MAYNE PHARMA Topical foam composition
Feb, 2030

(7 years from now)

US8808716 MAYNE PHARMA Topical foam composition
Feb, 2030

(7 years from now)

Drugs and Companies using TAZAROTENE ingredient

Market Authorisation Date: 11 May, 2012

Treatment: Topical treatment of acne vulgaris in patients 12 years of age or older

Dosage: AEROSOL, FOAM;TOPICAL

More Information on Dosage

4. List of Lexette drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11020407 MAYNE PHARMA Corticosteroid containing foam compositions and method of manufacture thereof
Nov, 2036

(13 years from now)

US10857159 MAYNE PHARMA Halobetasol foam composition and method of use thereof
Nov, 2036

(13 years from now)

US10857159

(Pediatric)

MAYNE PHARMA Halobetasol foam composition and method of use thereof
May, 2037

(14 years from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) Aug 18, 2024

Drugs and Companies using HALOBETASOL PROPIONATE ingredient

Market Authorisation Date: 24 May, 2018

Treatment: For the topical treatment of plaque psoriasis in patients 18 years of age and older

Dosage: AEROSOL, FOAM;TOPICAL

How can I launch a generic of LEXETTE before it's patent expiration?
More Information on Dosage

5. List of Nextstellis drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7732430 MAYNE PHARMA Drug delivery system comprising a tetrahydroxilated estrogen for use in hormonal contraception
Mar, 2025

(2 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 15, 2026

Drugs and Companies using DROSPIRENONE; ESTETROL ingredient

NCE-1 date: April, 2025

Market Authorisation Date: 15 April, 2021

Treatment: Use by females of reproductive potential to prevent pregnancy

Dosage: TABLET;ORAL

More Information on Dosage

6. List of Sorilux drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8629128 MAYNE PHARMA Vitamin formulation
May, 2026

(3 years from now)

US8263580 MAYNE PHARMA Vitamin formulation
May, 2028

(5 years from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) Nov 5, 2022

Drugs and Companies using CALCIPOTRIENE ingredient

Market Authorisation Date: 06 October, 2010

Treatment: Use of a calcipotriene containing foam for the treatment of psoriasis; Use of calcipotriene foam for the topical treatment of plaque psoriasis in patients aged 18 years and older; Use of calcipotriene foam for the topical treatment of plaque psoriasis in patients aged 4 years and older

Dosage: AEROSOL, FOAM;TOPICAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic